MGMT and glioblastoma: The cohort for the PRIDE trial will consist of patients with glioblastoma who meet the following criteria: isocitrate dehydrogenase wild-type (IDH wt), MGMT non-methylated, aged between 18 and 70 years, and clinically eligible to receive temozolomide (TMZ) and BEV.